. 2015 May 9;17(5):1041–1054. doi: 10.1208/s12248-015-9780-2

Table II.

List of FDA-approved inorganic nanoparticle products

Name	Material/functionality	Application/indication	Approval date
Feridex I.V.®; Endorem®	Iron oxide nanoparticles (coated with dextran)	Imaging of liver lesions	FDA approved (1996). Discontinued (2008)
Feridex I.V.®; Endorem®	Magnetic-field responsive for MRI imaging	Imaging of liver lesions	FDA approved (1996). Discontinued (2008)
Resovist®; Cliavist	Iron oxide nanoparticles (coated with carboxydextran)	Imaging of liver lesions	EMA approved (2001). Discontinued (2009)
Resovist®; Cliavist	Magnetic-field responsive for MRI imaging	Imaging of liver lesions	EMA approved (2001). Discontinued (2009)
Gastromark™; Lumirem®	Iron oxide nanoparticles (coated with silicone)	Enhance bowel imaging (oral administration)	FDA approved (1996). Discontinued (2012)
Gastromark™; Lumirem®	Magnetic-field responsive nanoparticles for MRI imaging	Enhance bowel imaging (oral administration)	FDA approved (1996). Discontinued (2012)
Ferumoxtran-10; Combidex®; Sinerem®	Iron oxide nanoparticles (coated with dextram)	Lymph node metastases imaging	Approved in some European countries. Application withdrawn from EMA (Sinerem 2007). Application withdrawn from FDA (2005)
Ferumoxtran-10; Combidex®; Sinerem®	Magnetic-field responsive for MRI imaging	Lymph node metastases imaging
Feraheme®; Rienso®; Ferumoxytol	Iron oxide nanoparticles (coated with polyglucose sorbitol carboxymethylether)	Treatment of iron deficiency in adults with chronic kidney disease	FDA approved (2009)